FIELD: medicine.
SUBSTANCE: claimed is application of vardenafil or its salt, hydrate or salt hydrate for preparation of pharmaceutical composition for treatment of disease from group of diseases, that includes syndrome of infravesical obstruction (SIVO), genitourinary disorders, which include syndrome of neurogenic urinary bladder (NUB), urinary incontinence (UI), such as mixed, acute, stress or incontinence caused by overfill, pain in pelvis, benign and malignant diseases of organs constituting genitourinary system in men and women, kidney diseases, such as acute and chronic renal failure, immunologically induced kidney diseases such as renal transplant rejection, lupus nephritis, kidney diseases caused by immune complexes, glomerulonephritis, nephritis, toxic nephropathy, and obstructive uropathies in mammals, as well as for treatment of neurogenic urinary bladder, superactive urinary bladder and intersticial cystitis and corresponding pharmaceutical compositions.
EFFECT: demonstrated is relaxation of smooth muscles of urinary bladder and increase of urination interval under effect of vardenafil.
4 cl, 6 dwg, 4 ex
